Tocilizumab biosimilar - Dr Reddys Laboratories
Alternative Names: DRL-TC; DRL_TCLatest Information Update: 28 Jun 2024
At a glance
- Originator Dr Reddys Laboratories
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
- No development reported Giant cell arteritis
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Giant-cell-arteritis(In volunteers) in Australia (SC, Injection)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Giant-cell-arteritis(In volunteers) in India (SC, Injection)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Giant-cell-arteritis(In volunteers) in New Zealand (SC, Injection)